⌕
Denali Therapeutics · DNLI · Nasdaq
Tenet 54 · Mixed
Compare
$18.08−3.52%At closeTenet 54 · Mixed
$18.08−0.66 (−3.52%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Denali Therapeutics (DNLI) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

15 figures withheld by our checks. Each blank figure names its reason.

Estimates are in the company's reporting currency and are not compared to the USD share price on this page. Filed figures are in US dollars. Nothing here converts between the two.
Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Denali Therapeutics to lose 1.75 a share in FY26 and 0.32 in FY30. 11 analysts publish an estimate for FY26 and 5 for FY30.

Forward P/E · FY26E
Not shown
the estimate and the price are in different currencies
FY26 EPS revisions · 30 days
▲ +23.4%
−2.29 to −1.75, one fiscal year at both ends
Disagreement · FY26
0.15
wide, −1.84 to −1.69
Coverage · FY26
11 · 15
EPS estimates · revenue estimates
Work out what the consensus implies at a multiple you chooseConsensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Are estimates going up or down lately?

The FY26 EPS consensus is −1.75, a loss that narrowed 27.2% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−4.9%+13.6%+32.1%FY26 +27.2%FY27 +7.4%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 6
FY2611 analysts▲ +23.4%−2.29 to −1.75▲ +27.2%−2.41 to −1.75▲ +28.7%−2.46 to −1.75
FY2713 analysts▲ +3.7%−2.35 to −2.26▲ +7.4%−2.44 to −2.26▲ +5.6%−2.39 to −2.26
Sep '2611 analysts▲ +26.9%−0.37 to −0.27▲ +54.5%−0.60 to −0.27▲ +50.9%−0.55 to −0.27
Dec '269 analysts▲ +3.3%−0.63 to −0.61▲ +10.0%−0.67 to −0.61▲ +10.0%−0.67 to −0.61

Contributors at both ends of the window: FY26 14 and 11. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

The near-year consensus is −1.75 a share in the company's reporting currency, and a ratio carries no currency, so a multiple can still be chosen. We stop before the product: it would be a price in the reporting currency, and this share trades in US dollars.

Consensus EBITDA · FY26
−0.3B
11 analysts · low −0.3B, high −0.3B · thin coverage
Multiple · EV/EBITDA · yours
No year of positive EBITDA or earnings on record to take a default from, so the multiple can only be yours.
Receipt · DNLI · FY26Nov 13, 2026
Implied, a share
Not computed

We do not convert currencies here. The estimate is in the reporting currency and the share trades in US dollars, so the product would be a price in neither.

Drag the multipleShaded: where Denali Therapeutics' P/E sat at each fiscal year end, FY20 to FY20. Each dot is one year.
117×

Each point on the line is a multiple, and the flag is the price it implies for FY26. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Not computed across currencies. The consensus is in Denali Therapeutics' reporting currency and the share trades in US dollars, so there is no multiple of this year's estimate to set against a growth rate.

How much do analysts disagree?

For FY30, estimates run from −0.63 to −0.12 around an average of −0.32, drawn by 5 analysts.

FY26E11 analysts
−1.84 to −1.69 · 0.15 wide
FY27E13 analysts
−3.17 to −1.86 · 1.31 wide
FY28E13 analysts
−2.41 to −0.77 · 1.63 wide
FY29E10 analysts
−2.44 to −0.45 · 1.99 wide
FY30E5 analysts
−0.63 to −0.12 · 0.51 wide

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. The last filed figure is in US dollars, so it is not placed on this axis. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Denali Therapeutics to lose 0.61 a share in the December quarter, the average of 9 estimates. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
31.7M
12 analysts, 28.2 to 52.0 in reporting ccy M

For the March quarter, analysts expect a loss of 0.58 a share.

Does Denali Therapeutics usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Denali Therapeutics begins on Jul 6, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '23
Our record, one quarter per report
Mar '24left out · currency
Jun '24left out · currency
Sep '24left out · currency
Dec '24left out · currency
Mar '25left out · currency
Jun '25left out · currency
Sep '25left out · currency
Dec '25left out · currency
Mar '26left out · currency
Jun '26left out · currency
Sep '26left out · currency
Dec '26not reported yet
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Denali Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 210.6% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

11 analysts publish an EPS estimate for FY26 and 15 publish revenue. Coverage thins with distance: 5 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
1511
FY26E
1513
FY27E
1513
FY28E
1010
FY29E
75
FY30E
The FY26 panel held 14 analysts when our record of it began on Jul 6, 2026 and holds 11 tonight.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · reporting ccy Bfiled · consensus average · band = low to high
−0.00.61.2historyStreet forecastFY22FY23FY30E

Coverage thins with distance: 15 revenue estimates for FY26, 7 for FY30.

Diluted EPS · reporting ccyfiled · consensus average · band = low to high
−3.35−1.670.01historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 11 EPS estimates for FY26, 5 for FY30.

Fiscal yearRevenue reporting ccy BYoYEPS reporting ccyYoYEBITDA reporting ccy BNet inc. reporting ccy BShares BAnalysts rev · EPSFwd P/E
FY25Filed · USD——−2.97————as filedn/m
FY26E0.10.0 to 0.1n/ca−1.75−1.84 to −1.69n/ca−0.3−0.30.1815 · 11—
FY27E0.20.1 to 0.3▲210.6%−2.26−3.17 to −1.86—−0.4−0.40.2015 · 13—
FY28E0.30.1 to 0.5▲95.2%−1.71−2.41 to −0.77—−0.4−0.40.2215 · 13—
FY29E0.40.2 to 0.8▲36.6%−1.24−2.44 to −0.45—−0.2−0.20.1810 · 10—
FY30E0.70.3 to 1.2▲55.6%−0.32−0.63 to −0.12n/cb−0.0−0.10.187 · 5—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 11 EPS estimates for FY26, 15 for revenue. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.